Compare Roundhill Magnificent Seven ETF (MAGS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Novo Nordisk A/S — how do they compare? Roundhill Magnificent Seven ETF trades at $73.75 (market cap $5.78B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 28.6× Roundhill Magnificent Seven ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Novo Nordisk A/S for 116 Days on average.
| MAGS | NVO | |
|---|---|---|
Market Cap | $5.78B | $165.31B |
Volume | 4,410,665 | 11,432,838 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $63.98 |
52-Week Low | $55.39 | $35.29 |
Typical Hold Time | 36 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.66, showing minimal daily movement with a slight 0.04% decline. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides equal-weighted exposure to the Magnificent Seven mega-cap tech stocks, though recent performance has trailed broader market indexes with modest 2% year-to-date gains.
The outlook remains cautiously optimistic given the ETF's concentrated tech exposure and AI growth themes. Key risks include market concentration, valuation concerns, and potential regulatory scrutiny. Wall Street sentiment appears mixed as investors weigh long-term AI potential against near-term performance challenges.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
